Jci_page_head_homepage_01 Jci_page_head_homepage_02
Maki Nakayama, Joshua N. Beilke, Jean M. Jasinski, Masakazu Kobayashi, Dongmei Miao, Marcella Li, Marilyne G. Coulombe, Edwin Liu, John F. Elliott, Ronald G. Gill, George S. Eisenbarth
Published in Volume 117, Issue 7
J Clin Invest. 2007; 117(7):1835–1843 doi:10.1172/JCI31368
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9
Development of IAAs in wild-type B16:Y NOD/SCID mice after splenocyte transfer.

(A) Splenic CD4+ T cells from B16:A-dKO mice immunized with native B16:Y insulin B:9–23 peptide were transferred to wild-type B16:Y NOD/SCID mice along with non-CD4+ splenocytes from unmanipulated double insulin-knockout mice. (B) Splenic CD4+ T cells from unmanipulated mice were transferred to wild-type B16:Y NOD/SCID mice along with a non-CD4+ splenocyte population from mice immunized with B16:Y insulin B:9–23 peptide. Each line represents an individual mouse.